Hims & Hers: Still Huge Potential Ahead
Hims & Hers Health, Inc is a telehealth platform offering tailored health and wellness services, showing significant stock volatility recently. HIMS experienced a dramatic rise from $24.11 to $68.7...
Hims & Hers: Peptide And Short Squeeze Are Coming!
Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1, positioning itself as a leader in the biohacking and longevity markets. The company's strategic mo...
What's Happening With HIMS Stock?
Hims & Hers Health (NYSE: HIMS), a telehealth platform, experienced an 8% increase in its stock on Friday, May 30th, following the announcement of a 4% reduction in its workforce. This move comes a...
Hims to cut 4% of workforce amid ban on weight-loss drug copies
Telehealth platform Hims & Hers said on Friday it will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy.
Hims & Hers Health Stock: After Doubling, It May Be Too Late To Buy
Hims & Hers Health shows strong growth in subscribers, revenue, and profitability, driven by expanding offerings and strategic partnerships, especially in weight loss and dermatology. HIMS posted s...
Hims & Hers Stock Falls Despite the Latest Wegovy Availability Offer
HIMS launches six-month Wegovy access at $549/month, aiming to expand affordable obesity care with holistic weight loss solutions.
Hims & Hers Health: New Guidance Creates Huge Risk For Shorts
Hims & Hers Health continues to fire on all cylinders as a business, growing at extraordinary rates while also improving its margins. Today, I will offer a unique and simplified view of the busines...
Up 157% in 2025, Is It Too Late to Buy Hims & Hers Stock?
Hims & Hers (HIMS -5.42%) has put investors on a roller coaster ride in 2025.
Hims & Hers Stock Chart Points to Strong Bullish Continuation
Hims and Hers, Inc. NYSE: HIMS shows strongly bullish signs that begin and end with the stock price action. It reflects volatility, but the bias is upward with rising support and the most recent sw...
Hims & Hers: Growth, Strategic Partnerships, And Operational Leverage (Upgrade)
Hims & Hers Health's rapid revenue and subscriber growth, plus improving cash generation, highlight strong business momentum and brand strength. Gross margins have declined due to lower-margin obes...
Hims & Hers Health Stock: A Rare High-Growth Value Play In Plain Sight
Rarely I see high-growth, value plays in the market. I think Hims & Hers Health is such a rare case: a world-class, high-growth company still being valued as a risky startup. A DCF model based on 2...
Hims & Hers: Wegovy Deal Opens New Growth Chapter - Missed The Rally? Selling Puts Could Yield 30%
Hims & Hers Health rebounded from a 60% stock drop by partnering with Novo Nordisk, offering Wegovy at a competitive price, boosting accessibility and growth. Q1 earnings were exceptional with 111%...
Hims & Hers Health, Inc. (HIMS) Q1 2025 Earnings Call Transcript
Hims & Hers Health, Inc. (NYSE:HIMS ) Q1 2025 Earnings Conference Call May 5, 2025 5:00 PM ET Company Participants Bill Newby - Head of Investor Relations Andrew Dudum - Co-Founder and Chief Execut...
Hims & Hers Health, Inc. (HIMS) Beats Q1 Earnings and Revenue Estimates
Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.05 per share a year ago.
Hims & Hers (HIMS) Blows Out Earnings Expectations
Hims & Hers Health, Inc. reported a strong financial performance for Q1 2025, with revenue reaching $586 million, marking a 111% increase year-over-year.
Related Companies